Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma-Reply
JAMA Oncol
.
2021 Apr 1;7(4):635-636.
doi: 10.1001/jamaoncol.2020.8020.
Authors
Smith Giri
1
,
Susan Bal
1
,
Luciano J Costa
1
Affiliation
1
Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham.
PMID:
33599690
DOI:
10.1001/jamaoncol.2020.8020
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal / adverse effects
Bortezomib
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Substances
Antibodies, Monoclonal
daratumumab
Bortezomib